TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25958936

Group type: EXPERIMENTAL
Intervention: Sleep disturbance measured at 6 weeks using Beck Depression Inventory (v.2) item 16.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Sleep disturbance at 4 months.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Anxiety and depression assessed by the Hospital Anxiety and Depression Scale.
Number of subjects: 134
Study: 25260214

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Present Centered Therapy (PCT)
Number of subjects: 11
Study: 21988096

Group type: EXPERIMENTAL
Intervention: TND + MI
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: TND-Only
Number of subjects: 1186

Group type: COMPARATOR
Intervention: SCC
Number of subjects: 1186
Study: 19874634

Group type: EXPERIMENTAL
Intervention: High-protein breakfast with whey
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-protein breakfast with alpha-lac
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal-protein breakfast
Number of subjects: 35
Study: 16938153

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil-propofol
Number of subjects: 60
Study: 16275243

Group type: EXPERIMENTAL
Intervention: Oxiplex/AP Gel
Number of subjects: 28

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 28
Study: 12101459

Group type: EXPERIMENTAL
Intervention: AMO 'ARRAY' multifocal IOLs
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Storz 'TRUEVISTA' bifocal IOLs
Number of subjects: 69

Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 69
Study: 9857882

Group type: EXPERIMENTAL
Intervention: Sarpogrelate 200 mg orally administered
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (without sarpogrelate)
Number of subjects: 22
Study: 7596637

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mebendazole (MBZ)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (neither DEC nor MBZ)
Number of subjects: 80
Study: 2228077

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories (100 mg 1‐3 times a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26375

Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% solution at pH 4.1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% solution at pH 5.8
Number of subjects: 24
Study: 30129937

Group type: COMPARATOR
Intervention: Amitriptyline (AMI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NOR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both AMI and NOR
Number of subjects: 50
Study: 29880554

Group type: EXPERIMENTAL
Intervention: Contact aspiration
Number of subjects: 231

Group type: COMPARATOR
Intervention: Stent retriever
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Contact aspiration and Stent retriever
Number of subjects: 231
Study: 27802960

Group type: EXPERIMENTAL
Intervention: 5-layered soft silicone foam dressing
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 366
Study: 24582071

Group type: EXPERIMENTAL
Intervention: INRPlus electronic assistant
Number of subjects: 551

Group type: COMPARATOR
Intervention: Standard fluindione management (control)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: INRPlus electronic assistant (compliant patients)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: INRPlus electronic assistant (non-compliant patients)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Control group (reference patients)
Number of subjects: 551
Study: 22169588

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 47
Study: 19156082

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 17485058

Group type: EXPERIMENTAL
Intervention: Vacuum therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional gauze therapy
Number of subjects: 54
Study: 15168040

Group type: EXPERIMENTAL
Intervention: High intake diet (810 g/10 MJ of vegetables, berries, and apple)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low intake diet (196 g/10 MJ of vegetables, berries, and apple)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (19 healthy volunteers)
Number of subjects: 77
Study: 11248360

Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg twice daily for 3 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study: 9676168

Group type: COMPARATOR
Intervention: PTCA alone (n = 208)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PTCA plus heparin-coated stent (n = 202)
Number of subjects: 410
Study: 8088182

Group type: EXPERIMENTAL
Intervention: Lipiodolization with gelatin sponge (Group A, n = 24)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Lipiodolization alone (Group B, n = 28)
Number of subjects: 52
Study: 2573301

Group type: EXPERIMENTAL
Intervention: Topically applied azatadine base
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemically administered terfenadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemically administered cetirizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4232743

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30528653

Group type: COMPARATOR
Intervention: Prostate-only IMRT (PO) 74 Gy/37 fractions
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Prostate and pelvic lymph node IMRT (P&P) 74 Gy/37 fractions to prostate, 60 Gy/37 fractions to pelvis
Number of subjects: 124
Study: 29247107

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kg daily) plus rituximab (375 mg/m2 weekly)
Number of subjects: 140

Group type: COMPARATOR
Intervention: High-dose prednisolone (1 mg/kg daily) plus rituximab
Number of subjects: 140
Study: 26011742

Group type: EXPERIMENTAL
Intervention: Crushed ALO-02 (30 mg oxycodone/3.6 mg naltrexone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oxycodone immediate-release (IR) (30 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24360132

Group type: EXPERIMENTAL
Intervention: rTMS and psychotherapy for an average of 21 sessions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 90
Study: 22302679

Group type: EXPERIMENTAL
Intervention: ARR plus elevated serum aldosterone concentration (SAC)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Log‐ARR
Number of subjects: 466

Group type: COMPARATOR
Intervention: ARR
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: ARR plus SAC
Number of subjects: 466
Study: 20205018

Group type: EXPERIMENTAL
Intervention: E-mail invitation from a friend
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Weak arguments in e-mail invitations
Number of subjects: 432

Group type: COMPARATOR
Intervention: E-mail invitation from an institution
Number of subjects: 432
Study: 17213965

Group type: EXPERIMENTAL
Intervention: Moderate exercise (60% of heart rate reserve)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Moderately-intense exercise (70% of heart rate reserve)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Movie-watching control group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All exercise groups combined
Number of subjects: 59
Study: 15908836

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 12111873

Group type: EXPERIMENTAL
Intervention: Incorporation of baseline covariates in estimating equations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm only
Number of subjects: 0
Study: 10360713

Group type: EXPERIMENTAL
Intervention: Monthly measurement of access flow (QAT)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Monthly measurement of static venous pressure (VPS)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (no monthly monitoring)
Number of subjects: 103
Study: 7585753

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2008802

Group type: EXPERIMENTAL
Intervention: Vaccine A (oral, 3 doses at 14-day intervals)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vaccine B (oral, 3 doses at 14-day intervals)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (100 ml 5% NaHCO3, oral, 3 doses at 14-day intervals)
Number of subjects: 3
Study: 7121333

Group type: EXPERIMENTAL
Intervention: Primary Care Curriculum (PCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Curriculum
Number of subjects: 0
Study: 29580634

Group type: EXPERIMENTAL
Intervention: D-Cycloserine (DCS) 100 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 28832388

Group type: EXPERIMENTAL
Intervention: Non‐op treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: OP treatment with hook plate fixation
Number of subjects: 83
Study: 25823991

Group type: EXPERIMENTAL
Intervention: 10 g Fibersol-2
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0 g Fibersol-2 (Control)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 5 g Fibersol-2
Number of subjects: 19
Study: 23716156

Group type: EXPERIMENTAL
Intervention: 50,000 IU of vitamin D3 per month (Group A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 100,000 IU of vitamin D3 per month (Group B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 200,000 IU of vitamin D3 initially, then adjusted to 50,000 IU per month (Group C)
Number of subjects: 51
Study: 21151012

Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin A1c (HbA1c) quintiles
Number of subjects: 19858

Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin A1c (HbA1c) clinical cutpoints
Number of subjects: 19858

Group type: COMPARATOR
Intervention: Adjustment for body mass index (BMI)
Number of subjects: 19858
Study: 19796732

Group type: EXPERIMENTAL
Intervention: Cervical Pessary
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerclage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Progesterone
Number of subjects: 0
Study: 17585259

Group type: EXPERIMENTAL
Intervention: Release of the talocalcaneal interosseous ligament (TCIL)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No release of the talocalcaneal interosseous ligament (TCIL)
Number of subjects: 46
Study: 15036674

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatinum based combination chemotherapy (with adriamycin or methotrexate)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group (no neoadjuvant chemotherapy)
Number of subjects: 620
Study: 11437193

Group type: EXPERIMENTAL
Intervention: 18-lesson, 6-month classroom curriculum to reduce television, videotape, and video game use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control school (no intervention)
Number of subjects: 0
Study: 9612112

Group type: EXPERIMENTAL
Intervention: Topical treatment of factor XIII twice daily for ten days (treatment group, n = 16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 24
Study: 7838916

Group type: EXPERIMENTAL
Intervention: R10 min/3 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R1h/5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R4h/9 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8
Study: 3377148

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.05 mg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.1 mg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.2 mg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.05 mg/kg
Number of subjects: 18
Study: 31130558

Group type: EXPERIMENTAL
Intervention: Mountain residents
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Downtown residents
Number of subjects: 1346
Study: 29373645

Group type: EXPERIMENTAL
Intervention: External stenting of SVGs (17 SVGs in left territory, 18 SVGs in right territory)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-stented SVGs (20 SVGs in left territory, 18 SVGs in right territory)
Number of subjects: 35
Study: 28720079

Group type: EXPERIMENTAL
Intervention: Peer-led physical activity intervention
Number of subjects: 408

Group type: COMPARATOR
Intervention: Usual center programming
Number of subjects: 408
Study: 26174719

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic arm (200 mg of atazanavir twice daily for patients with unfavourable genotypes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard-dose arm (400 mg of atazanavir once daily)
Number of subjects: 80
Study: 23429637

Group type: EXPERIMENTAL
Intervention: Mobile app for physical activity self-monitoring
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mobile app for dietary self-monitoring
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-app users for physical activity self-monitoring
Number of subjects: 96

Group type: COMPARATOR
Intervention: Paper journal users for dietary self-monitoring
Number of subjects: 96
Study: 20840347

Group type: EXPERIMENTAL
Intervention: synchronous balneophototherapy (sBPT) consisting of narrowband UVB PT with 311 nm and synchronous bathing in 10% Dead Sea salt solution
Number of subjects: 367

Group type: COMPARATOR
Intervention: narrowband UVB phototherapy (PT) alone
Number of subjects: 367
Study: 19819665

Group type: EXPERIMENTAL
Intervention: SC morphine plus rHuPH20 (150U)
Number of subjects: 13

Group type: COMPARATOR
Intervention: SC morphine plus placebo (normal saline)
Number of subjects: 13

Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 13
Study: 16723653

Group type: EXPERIMENTAL
Intervention: Implant Group (n = 62)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Denture Group (n = 56)
Number of subjects: 118
Study: 15622663

Group type: EXPERIMENTAL
Intervention: Parecoxib 20 mg i.m.
Number of subjects: 353

Group type: COMPARATOR
Intervention: Ketorolac 30 mg i.m.
Number of subjects: 353
Study: 11689738

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20 g x d(‐1) for 5 days, then 5 g x d(‐1) for 5 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (cornstarch, same dosage regimen as Cr group)
Number of subjects: 19
Study: 9142590

Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional Unsynchronized Intermittent Mandatory Ventilation (IMV)
Number of subjects: 17
Study: 8196995

Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation (HFJV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 9
Study: 2574108

Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 240

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 240
Study: 1103750

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo aerosols
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 31783127

Group type: EXPERIMENTAL
Intervention: Working memory span intervention for 20 sessions over 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 31218889

Group type: EXPERIMENTAL
Intervention: Run Zao Zhi Yang capsule (RZZYC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: COMPARATOR
Intervention: Run Zao Zhi Yang capsule (RZZYC) and Placebo
Number of subjects: 240
Study: 29192639

Group type: EXPERIMENTAL
Intervention: 15 mg ropivacaine 1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg ropivacaine 1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 25 mg ropivacaine 1%
Number of subjects: 60
Study: 26562074

Group type: EXPERIMENTAL
Intervention: PEMF treatment (MAGCELL ARTHRO device), delivered a sinusoidal magnetic field of 4-12 Hz, magnetic flux density of 105 mT, treatment twice a day for 5 min over 18 days.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo treatment (placebo device)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PEMF treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 57
Study: 23415013

Group type: EXPERIMENTAL
Intervention: Clopidogrel alone (double therapy)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (triple therapy)
Number of subjects: 573
Study: 21531587

Group type: COMPARATOR
Intervention: Foam sclerotherapy with compression stockings (CG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Foam sclerotherapy without compression stockings (WCG)
Number of subjects: 40
Study: 19881375

Group type: EXPERIMENTAL
Intervention: Excisions performed along the visible outer margins of erythema or induration area surrounding the tumor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional wide excision with wide skin margins
Number of subjects: 0
Study: 17190414

Group type: EXPERIMENTAL
Intervention: Vestibular autorotation test (VAT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Videonystagmography (VNG) test
Number of subjects: 73

Group type: COMPARATOR
Intervention: Caloric test
Number of subjects: 73
Study: 14708047

Group type: COMPARATOR
Intervention: Early-onset group (under age 40)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Expression of p53 in early-onset group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Late-onset group (over age 40)
Number of subjects: 70
Study: 10793598

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (group A, n = 28)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No cricoid pressure (group B, n = 25)
Number of subjects: 53
Study: 9238392

Group type: EXPERIMENTAL
Intervention: Twin pairs (monozygotic)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Twin pairs (dizygotic)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Monozygotic twin pairs
Number of subjects: 62
Study: 1731135

Group type: EXPERIMENTAL
Intervention: Extensive ethics education intervention (EI)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Limited intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patients with AIDS
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patients with other diagnoses
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patients with malignancy
Number of subjects: 88
Study: 6393945

Group type: EXPERIMENTAL
Intervention: Low fat, high unrefined carbohydrate (HC) diet
Number of subjects: 5

Group type: COMPARATOR
Intervention: Low carbohydrate (LC) diet
Number of subjects: 5
Study: 30879003

Group type: EXPERIMENTAL
Intervention: AZD1981 40 mg TID
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 29299989

Group type: EXPERIMENTAL
Intervention: Curcumin 1000mg with 10mg of piperine daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 27195662

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best contemporary metallic drug-eluting stents (DES)
Number of subjects: 0
Study: 24843205

Group type: EXPERIMENTAL
Intervention: Dembone® (freeze-dried bone allograft)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: G-Bone® (modified hydroxyapatite)
Number of subjects: 30
Study: 23529988

Group type: EXPERIMENTAL
Intervention: Active diet (baked products enriched with β‐glucans, folic acid, long‐chain and short‐chain n‐3 fatty acids, tocopherols)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Active diet
Number of subjects: 16
Study: 19321117

Group type: EXPERIMENTAL
Intervention: 100% lyocell clothing and bedding
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100% cotton clothing and bedding
Number of subjects: 30
Study: 17965442

Group type: EXPERIMENTAL
Intervention: C5aR-antagonist AcF-(OpdChaWR) (PMX53)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15200658

Group type: EXPERIMENTAL
Intervention: Pentobarbital (PB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chloral hydrate (CH)
Number of subjects: 100
Study: 11753768

Group type: EXPERIMENTAL
Intervention: Specific back muscle exercises
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Non-specific fitness training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive treatment or no treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison of specific back muscle exercises and non-specific fitness training
Number of subjects: 12
Study: 9586884

Group type: EXPERIMENTAL
Intervention: Standard-dose cranial irradiation (SRT) of 36 Gy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reduced-dose cranial irradiation (RRT) of 23.4 Gy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Younger patients (Y/SRT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Older patients (O/RRT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Younger patients (Y/RRT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Older patients (O/SRT)
Number of subjects: 22
Study: 7988168

Group type: EXPERIMENTAL
Intervention: 2-day suicide intervention training program
Number of subjects: 36
Study: 2645441

Group type: EXPERIMENTAL
Intervention: Saphenous vein patch closure (n = 62)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Primary closure (n = 60)
Number of subjects: 136
Study: 31174214

Group type: EXPERIMENTAL
Intervention: Dietary fiber intake
Number of subjects: 345
Study: 28892496

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Corn-soy blend (CSB)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: LNS with soy isolate (SI)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: LNS with dehulled soy (DS)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Soy isolate (SI)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Dehulled soy (DS)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: 20% milk protein
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: 50% milk protein
Number of subjects: 1609
Study: 25809413

Group type: EXPERIMENTAL
Intervention: Prednisone at 0.75 mg/kg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66